US Niaspan scripts are down only 5% as a result of the AIM-HIGH study, according to ABT’s 2Q11 CC, so this product is indeed stickier than some investors and analysts thought.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”